

**Priority Health Medicare prior authorization form**

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to:  Medicare Part B  Medicare Part D  
 This request is:  Expedited request  Standard request

Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting.

**Daklinza<sup>TM</sup>** (daclatasvir)

**Member**

Last Name: \_\_\_\_\_ First Name: \_\_\_\_\_  
 ID #: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Primary Care Physician: \_\_\_\_\_  
 Requesting Provider: \_\_\_\_\_ Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_  
 Provider Address: \_\_\_\_\_  
 Provider NPI: \_\_\_\_\_ Contact Name: \_\_\_\_\_  
 Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_

What is the provider's specialty?

Gastroenterologist  Hepatologist  Infectious disease specialist  Other: \_\_\_\_\_

**Drug information**

New Request  Continuation Request  
 Daklinza 60mg tablet **Start date** (or date of next dose): \_\_\_\_\_  
 Daklinza 30mg tablet **Date of last dose** (if applicable): \_\_\_\_\_  
**Dosing frequency:** \_\_\_\_\_  
 Requested Duration:  12 weeks  24 weeks  Other \_\_\_\_\_

**Prior authorization criteria**

The following requirements need to be met before this drug is covered by Priority Health Medicare. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

1. Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist
2. Must be age 18 or older
3. Must have a diagnosis of chronic hepatitis C infection
4. If hepatitis C genotype 1, 5, or 6, must first try Harvoni
5. If hepatitis C genotype 2 or 3, must first try Epclusa

**Additional information**

**Note:** Criteria (including criteria for duration of approval) will be applied consistent with current AASLD/IDSA (American Association for the Study of Liver Disease/Infectious Disease Society of America) guidelines

**Medically accepted indication**

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*:

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- — or — supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information and the DRUGDEX Information System)

**Priority Health Precertification Documentation**

**A. What condition is this drug being requested for?**

- Chronic hepatitis C infection  
 Other – the patient’s condition is: \_\_\_\_\_

**B. What is the patient’s HCV genotype?**

- 1a  1b  2  3  4  5  6

**C. Has the patient previously received treatment for chronic hepatitis C?**

- Yes, the drug(s) used were: \_\_\_\_\_  
 No

**D. If genotype 1, 5, or 6, has the patient first tried Harvoni?**

- Yes, for \_\_\_\_\_ weeks from \_\_\_\_\_ (list dates)  
 No, because \_\_\_\_\_

**E. If genotype 2 or 3, has the patient first tried Epclusa?**

- Yes, for \_\_\_\_\_ weeks from \_\_\_\_\_ (list dates)  
 No, because \_\_\_\_\_

**F. What drug combination will be used with Daklinza? \_\_\_\_\_**

**G. Does the patient have liver cirrhosis?**

- Yes  Compensated  Decompensated  
 No

**H. What is the patient’s current pre-treatment HCV RNA? \_\_\_\_\_ IU/mL**

*(This information is needed to determine the appropriate duration of therapy based on current guidelines.)*

**Priority Health Medicare exception request**

**Do you believe one or more of the prior authorization requirements should be waived?**  Yes  No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

**Would Daklinza likely be the most effective option for this patient?**

- No  
 Yes, because: \_\_\_\_\_

**If the patient is currently using Daklinza, would changing the patient's current regimen likely result in adverse effects for the patient?**

No

Yes, because: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_